Asset Details
Do you wish to reserve the book?
MDCT of the liver in obese patients: evaluation of a different method to optimize iodine dose
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
MDCT of the liver in obese patients: evaluation of a different method to optimize iodine dose
Do you wish to request the book?
MDCT of the liver in obese patients: evaluation of a different method to optimize iodine dose
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
MDCT of the liver in obese patients: evaluation of a different method to optimize iodine dose
2017
Overview
Purpose
To prospectively compare two different approaches for estimating the amount of intravenous contrast media (CM) needed for multiphasic MDCT of the liver in obese patients.
Materials and methods
This single-center, HIPAA-compliant prospective study was approved by our Institutional Review Board. Ninety-six patients (55 men, 41 women), with a total of 42 hypovascular liver lesions, underwent MDCT of the liver. The amount of contrast medium injected was computed according to the patient’s lean body weight which was estimated using either a bioimpedance device (Group A) or the James formula (Group B). The following variables were compared between the two groups: the amount of contrast medium injected (in grams of Iodine, gI), the contrast enhancement index (CEI) and the lesion-to-liver contrast-to-noise ratio.
Results
Protocols A and B yielded significant differences in the amount of CM injected (mean values 41.9 ± 4.41 gI in Group A vs. 35.9 ± 5.75 gI in Group B;
P
= 0.021). The mean CEI value and lesion-to-liver contrast-to-noise ratio measured on the portal phase were significantly higher with protocol A than with protocol B (
P
< 0.05).
Conclusions
Our study shows that the adoption of a bioimpedance device in obese patients improves liver parenchymal enhancement and lesion conspicuity.
Publisher
Springer US,Springer Nature B.V
Subject
/ Aged
/ Contrast Media - administration & dosage
/ Dosage
/ Female
/ Humans
/ Imaging
/ Iodine
/ Iopamidol - administration & dosage
/ Iopamidol - analogs & derivatives
/ Lesions
/ Liver
/ Liver Neoplasms - diagnostic imaging
/ Male
/ Medicine
/ Multidetector Computed Tomography - methods
/ Obesity
/ Patients
